Beam Therapeutics Names Sravan Emany Chief Financial Officer

Dow Jones

2024/12/06

By Colin Kellaher

Beam Therapeutics has hired Sravan Emany as the biotechnology company's next chief financial officer.

Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday.

Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay.

Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 06, 2024 07:16 ET (12:16 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2489890372"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489890372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489890372?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489890372","market":"sg","top_or_hot":-1,"title":"Beam Therapeutics Names Sravan Emany Chief Financial Officer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has hired Sravan Emany as the biotechnology company's next chief financial officer. \n</p>\n<p>\n  Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday. \n</p>\n<p>\n  Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay. \n</p>\n<p>\n  Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 06, 2024 07:16 ET (12:16 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Names Sravan Emany Chief Financial Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Names Sravan Emany Chief Financial Officer\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-06 20:16</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has hired Sravan Emany as the biotechnology company's next chief financial officer. \n</p>\n<p>\n  Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday. \n</p>\n<p>\n  Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay. \n</p>\n<p>\n  Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 06, 2024 07:16 ET (12:16 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2489890372","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489890372","pubTimestamp":1733487360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Beam Therapeutics has hired Sravan Emany as the biotechnology company's next chief financial officer.Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday.Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay.Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","BEAM":"Beam Therapeutics, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓"},"translate_title":"Beam Therapeutics任命Sravan Emany为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BEAM":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Beam Therapeutics has hired Sravan Emany as the biotechnology company's next chief financial officer. \n\n\n  Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday. \n\n\n  Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay. \n\n\n  Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 07:16 ET (12:16 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}